Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
Status:
Recruiting
Trial end date:
2022-11-18
Target enrollment:
Participant gender:
Summary
This Phase 1 study has been designed to determine the safety, tolerability and
pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use
conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis